NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

November 29, 2011

Primary Completion Date

November 17, 2015

Study Completion Date

November 17, 2015

Conditions

Urinary Bladder NeoplasmsCarcinoma, Transitional CellOvarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalTumor Virus Infections

Interventions

DRUG

CC-486

CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability

DRUG

Carboplatin

Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.

DRUG

ABI-007

ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2

Trial Locations (13)

21079

Centre Georges Francois Leclerc, Dijon

28007

Hospital General Universitario Gregorio Maranon, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29605

Greenville Hospital, Greenville

37205

Sarah Cannon Research Institute, Nashville

46202

Indiana University Cancer Center, Indianapolis

75005

Institut Curie, Paris

78229

South Texas Accelerated Research Therapeutics, San Antonio

85258

Scottsdale Healthcare Research Institute, Scottsdale

94115

University of California, San Francisco, San Francisco

48201-2014

Karmanos Cancer Institute, Detroit

1066 CX

The Netherlands Cancer Instiute Antoni Van Leeuwenhoekziekenhuis, Amsterdam

3015 CN

Erasmus Medical Center, Rotterdam